Heron Therapeutics | HRTX - Cash And Equivalent


Heron Therapeutics reported $20.72M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Veracyte USD 299.52M 36.38M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026